

# Anna Kreutzman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5070910/publications.pdf>

Version: 2024-02-01

28  
papers

769  
citations

516215

16  
h-index

580395

25  
g-index

31  
all docs

31  
docs citations

31  
times ranked

1042  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. <i>Blood</i> , 2010, 116, 772-782.	0.6	168
2	Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. <i>Leukemia</i> , 2011, 25, 1587-1597.	3.3	87
3	Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy. <i>Leukemia</i> , 2013, 27, 914-924.	3.3	84
4	Chronic Myeloid Leukemia Patients in Prolonged Remission following Interferon- $\alpha$ Monotherapy Have Distinct Cytokine and Oligoclonal Lymphocyte Profile. <i>PLoS ONE</i> , 2011, 6, e23022.	1.1	44
5	Enlarged Memory T-Cell Pool and Enhanced Th1-Type Responses in Chronic Myeloid Leukemia Patients Who Have Successfully Discontinued IFN- $\alpha$ Monotherapy. <i>PLoS ONE</i> , 2014, 9, e87794.	1.1	41
6	Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner. <i>Clinical Cancer Research</i> , 2017, 23, 6697-6707.	3.2	41
7	Dasatinib promotes Th1-type responses in granzyme B expressing T-cells. <i>Oncolmmunology</i> , 2014, 3, e28925.	2.1	38
8	Spatial immunoprofiling of the intratumoral and peritumoral tissue of renal cell carcinoma patients. <i>Modern Pathology</i> , 2021, 34, 2229-2241.	2.9	25
9	Immune cell phenotype and functional defects in Netherton syndrome. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 213.	1.2	22
10	Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia. <i>Experimental Hematology</i> , 2012, 40, 906-913.e1.	0.2	20
11	Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1543-1554.	1.2	20
12	Somatic mTOR mutation in clonally expanded T lymphocytes associated with chronic graft versus host disease. <i>Nature Communications</i> , 2020, 11, 2246.	5.8	20
13	Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line. <i>Oncolmmunology</i> , 2019, 8, e1638210.	2.1	19
14	Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 665-676.	2.0	18
15	CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia. <i>Biomarker Research</i> , 2020, 8, 54.	2.8	18
16	Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 717-730.	2.0	18
17	T and NK cell abundance defines two distinct subgroups of renal cell carcinoma. <i>Oncolmmunology</i> , 2022, 11, 1993042.	2.1	16
18	Poor cytokine-induced phosphorylation in chronic myeloid leukemia patients at diagnosis is effectively reversed by tyrosine kinase inhibitor therapy. <i>Experimental Hematology</i> , 2011, 39, 102-113.e1.	0.2	15

#	ARTICLE	IF	CITATIONS
19	Imatinib and pegylated IFN- $\alpha$ 2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response. <i>European Journal of Haematology</i> , 2014, 92, 413-420.	1.1	11
20	Immediate Effects of Dasatinib on the Migration and Redistribution of Naïve and Memory Lymphocytes Associated With Lymphocytosis in Chronic Myeloid Leukemia Patients. <i>Frontiers in Pharmacology</i> , 2019, 10, 1340.	1.6	11
21	Novel Hemizygous IL2RG p.(Pro58Ser) Mutation Impairs IL-2 Receptor Complex Expression on Lymphocytes Causing X-Linked Combined Immunodeficiency. <i>Journal of Clinical Immunology</i> , 2020, 40, 503-514.	2.0	11
22	IFN- $\alpha$ induces prolonged remissions modeling curative immunologic responses in chronic myeloid leukemia. <i>OncImmunology</i> , 2014, 3, e28781.	2.1	7
23	Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia. <i>PLoS ONE</i> , 2017, 12, e0171041.	1.1	7
24	Chronic Myeloid Leukemia Patients Undergoing Interferon Alpha Therapy Exhibit Normal Peripheral Blood Gamma Delta T Cells That May Be Expanded in Vitro to Generate Predominantly CD45RA-Positive Effector Memory Cells for Immunotherapy. <i>Blood</i> , 2012, 120, 3729-3729.	0.6	5
25	Clonal Expansion of T/NK-Cells during Tyrosine Kinase Inhibitor Dasatinib Therapy. <i>Blood</i> , 2008, 112, 573-573.	0.6	3
26	NK-Cells In Dasatinib-Treated Chronic Myeloid Leukemia Patients Display a Unique Phenotype Associated With Cytotoxic Potential. <i>Blood</i> , 2013, 122, 1475-1475.	0.6	0
27	CCR7 As a New Biomarker in Graft-Versus-Host Disease: T Cells Expressing the Homing Receptor CCR7 Mediate the Pathogenesis of Gvhd. <i>Blood</i> , 2014, 124, 3930-3930.	0.6	0
28	Single-Cell Roadmap of Immune Cell Response in Chronic Myeloid Leukemia. <i>Blood</i> , 2020, 136, 4-5.	0.6	0